Shares of Apellis Pharmaceuticals Inc. gained 5.1% in premarket trading on Friday after it shared details from a late-stage clinical trial evaluating its experimental drug pegcetacoplan against Alexion Pharmaceuticals Inc.'s Soliris as a treatment for paroxysmal nocturnal hemoglobinuria. The study found that pegcetacoplan was better than Soliris in improving hemoglobin levels in adults with the rare blood disease. Soliris brought in $3.9 billion in revenue in 2019. Apellis said it plans to submit a new drug application for pegcetacoplan to the Food and Drug Administration in the second half of the year. Its stock is down 0.5% year-to-date, while the S&P 500 has declined 7.1%.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Jack Fincham sends fans wild as he poses with his lookalike baby in rare snapJack Fincham, 29, took to Instagram to share the rare snap of his five-and-a-half month old baby girl he shares with ex Casey Ranger
続きを読む »
Kelly Clarkson Files For Divorce From Brandon Blackstock After Nearly 7 Years Of MarriageThe couple share two children together, daughter River Rose and son Remington Alexander.
続きを読む »
Minneapolis police are rarely disciplined for complaints, records showMinneapolis police officers who face complaints are rarely held accountable, a CNN investigation shows. Around 97% of the time, officers are not disciplined.
続きを読む »